Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company that develops RNA-based medicines to restore protein expression in severe genetic diseases. Its news flow is closely tied to the progress of its antisense oligonucleotide programs, particularly zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Investors following STOK news can expect regular updates on clinical development milestones. These include announcements on the global Phase 3 EMPEROR study of zorevunersen in children and adolescents with Dravet syndrome, multi-year data from open-label extension studies, and analyses comparing treated patients with natural history data. Stoke also reports on natural history research such as the FALCON study in ADOA, which informs the design of interventional trials like the OSPREY Phase 1 study of STK-002.
Regulatory and collaboration developments are another important category of news. Stoke highlights regulatory designations for zorevunersen, including orphan drug, rare pediatric disease, and Breakthrough Therapy Designation, as well as its strategic collaboration with Biogen, under which the companies jointly advance zorevunersen for Dravet syndrome with defined regional commercialization rights.
Corporate and financial updates appear in press releases and are often paired with SEC filings. These items cover quarterly financial results, cash runway commentary, stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in major healthcare and investor conferences. Webcasts and conference calls for analysts and investors are also announced through news releases.
For anyone researching STOK, the news stream provides context on how Stoke Therapeutics is advancing its TANGO antisense platform, executing clinical trials in rare neurological and ophthalmic diseases, and managing its partnerships and capital to support ongoing development.
Stoke Therapeutics (Nasdaq: STOK) announced CEO Edward M. Kaye, M.D., will present at two investor conferences. The events include the Stifel 3rd Annual CNS Day on March 31, 2021, at 2:00 PM ET, and the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 12:45 PM ET. Both presentations will be available via live audio webcast on the company's investor site, with replays accessible for 30 days post-event. Stoke Therapeutics focuses on treating severe diseases through RNA-based medicines, including its lead compound STK-001 for Dravet syndrome.
Stoke Therapeutics (Nasdaq: STOK) reported a net loss of $52.3 million for 2020, equating to $1.56 per share, an increase from $32.3 million or $1.80 per share in 2019. R&D expenses rose to $32.2 million from $23.8 million, while G&A expenses surged to $20.8 million from $11.9 million. The Phase 1/2a MONARCH study for STK-001 in Dravet syndrome is progressing, with initial dosing completed. Stoke holds $287.5 million in cash to support operations into 2024, focusing on advancing RNA-based therapies.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Edward M. Kaye, M.D., will present at the Barclays Global Healthcare Conference on March 11, 2021, at 3:35 p.m. ET. The presentation will focus on the company's innovative RNA-based medicines designed to up-regulate protein expression and address severe diseases. A live audio webcast will be available on the Investors & Media section of Stoke’s website, with a replay accessible for 30 days post-presentation. Stoke’s lead candidate, STK-001, is aimed at treating Dravet syndrome, a severe genetic epilepsy.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Edward M. Kaye, M.D., will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 4:30 p.m. ET. The company specializes in addressing the underlying causes of genetic diseases by upregulating protein expression. A live audio webcast of the presentation will be available on Stoke’s Investors & Media page, with a replay accessible for 30 days post-event. Stoke aims to innovate treatment for autosomal dominant haploinsufficiencies, restoring essential protein levels for better health outcomes.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a pioneering biotechnology company, announced that CEO Edward M. Kaye, M.D., will participate in a fireside chat at the Needham Virtual Epilepsy & Pain – Specialty Therapeutics Conference on December 10, 2020, at 12:45 p.m. ET. The live audio webcast will be accessible on Stoke’s Investors & Media section of their website, with a replay available for 30 days. Stoke focuses on treating genetic diseases by upregulating protein expression, targeting autosomal dominant haploinsufficiencies to potentially restore health.
Stoke Therapeutics (Nasdaq: STOK) presented data at the 2020 American Epilepsy Society Annual Meeting regarding STK-001, a potential treatment for Dravet syndrome. Key findings include a baseline analysis from the BUTTERFLY study indicating significant cognitive impairments in children with Dravet, even when treated with existing therapies. The MONARCH study is underway to assess the safety and efficacy of STK-001. Preclinical data show promise in addressing the genetic cause of Dravet syndrome by potentially modifying disease progression and improving patient quality of life.
Stoke Therapeutics (Nasdaq: STOK) announced four abstracts on Dravet syndrome for the upcoming American Epilepsy Society 2020 Virtual Annual Meeting. Highlights include baseline data from the BUTTERFLY study evaluating neurodevelopmental status in children, details on the ongoing Phase 1/2a MONARCH study of STK-001, and new preclinical data supporting the efficacy of a TANGO antisense oligonucleotide. STK-001 aims to be a disease-modifying therapy addressing the genetic cause of Dravet syndrome, which affects around 35,000 individuals in select regions.
Stoke Therapeutics (Nasdaq: STOK) has successfully closed its public offering of 2,875,000 shares at $39.00 each, raising approximately $105.1 million in net proceeds. The offering included 375,000 shares from underwriters' option. Funds will support research, clinical development, and manufacturing for their product candidates, including STK-001 for Autosomal Dominant Optic Atrophy and other general corporate purposes. This offering was conducted under a previously filed SEC registration statement.
Stoke Therapeutics (Nasdaq: STOK) has priced an underwritten public offering of 2,500,000 shares at $39.00 each, expecting to raise $97.5 million. The offering will close around November 24, 2020, subject to customary conditions. Stoke has provided underwriters a 30-day option to purchase an additional 375,000 shares. Proceeds will support research, clinical development of STK-001 for Autosomal Dominant Optic Atrophy, and general corporate needs. This offering follows a registration statement with the SEC.
Stoke Therapeutics (Nasdaq: STOK) has announced a proposed underwritten public offering of up to 2,500,000 shares of common stock, with a 30-day option for underwriters to purchase an additional 375,000 shares. Proceeds from the offering will fund research and clinical development for its product candidates, including the late-stage STK-001 and new treatments for Autosomal Dominant Optic Atrophy. The offering is subject to market conditions and there are no guarantees regarding completion or terms.